Gamma-aminobutyric acid type A receptor subunit beta 3 (GABRB3) (GABRB3)

The Gamma-aminobutyric acid type A receptor subunit beta 3 (GABRB3) is a critical component of the GABAA receptor, a pentameric ligand-gated ion channel that mediates fast inhibitory neurotransmission in the central nervous system (UniProt, 2024). This subunit is essential for the proper assembly, trafficking, and surface expression of functional GABAA receptors, particularly those involved in synaptic and extrasynaptic inhibition (MDPI, 2022). Beyond its role as a structural subunit, GABRB3 is involved in neurodevelopmental processes such as neurogenesis and the maturation of neuronal circuits (NIH, 2026). Genetic mutations or deletions in the GABRB3 gene are strongly linked to severe neurological conditions, including early-onset epileptic encephalopathies, autism spectrum disorders, and Angelman syndrome (Epilepsy Genetics, 2017). Pharmacologically, the beta 3 subunit is a primary target for several classes of drugs, including general anesthetics like etomidate and propofol, which exhibit selectivity for receptors containing this subunit (Guide to Pharmacology, 2024). It also serves as a site for positive allosteric modulation by benzodiazepines, barbiturates, and neurosteroids, which enhance the receptor's inhibitory activity (NIH, 2026). Recent studies have also identified GABRB3 expression in non-neuronal tissues, specifically in triple-negative breast cancer, where it may influence tumor cell proliferation and migration (TandfOnline, 2024). Consequently, GABRB3 is a significant therapeutic target for treating epilepsy and anxiety, and is being explored as a potential biomarker and target in oncology.

Other names

GABAA receptor beta 3 subunitGABA(A) receptor subunit beta-3GABAAR subunit beta-3Gamma-aminobutyric acid receptor subunit beta-3GABRB3

Positive allosteric modulation of the GABAA receptor chloride channel, increasing the frequency or duration of channel opening in response to GABA (NIH, 2026; Guide to Pharmacology, 2024).